Haleon plc logo

Haleon plc(HLN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$9.05
11/19/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for HLN

11/19/2026: HLN (1-star) is currently NOT-A-BUY. Pass it for now.

Haleon plc is a pure-play consumer healthcare company known for globally recognized everyday brands like Sensodyne, Panadol, and Centrum. The company benefits from resilient defensive demand, strong brand loyalty, and historically robust profit margins. Its primary investment story centers on steady organic growth, margin expansion, and consistent balance sheet deleveraging. Key risks include private-label competition, raw material inflation, and debt service obligations. The stock suits defensive or income-focused investors looking for stable consumer exposure, with ongoing debt reduction and cash generation remaining key developments to monitor.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitHaleon offers steady, mid-single-digit organic growth rather than high-octane hyper-growth characteristics.
Momentum investorStrong fit while signal remains positiveMomentum appeal depends on favorable technical breakouts supported by strong defensive earnings reports.
Value investorMixed fitValuation reflects stable defensive qualities, offering moderate upside depending on debt reduction progress.
Dividend investorStrong fitThe company provides a reliable dividend profile backed by predictable cash flows from everyday health products.
Low-risk investorStrong fitEssential consumer healthcare products provide lower cyclical volatility compared to discretionary or tech sectors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityLowDefensive consumer staples traits generally shield the stock from sharp macro market swings.
Valuation riskMediumShares can experience multiple compression if broader market interest rates rise significantly.
Competition risk (branded vs store-brands)Medium / highRetailer private-label alternatives continuously pressure market share during tight consumer budget cycles.
Business qualityStrongA portfolio of globally trusted household names underpins robust franchise durability.
Dividend incomeMediumPayouts are stable and backed by predictable cash generation, though yields remain moderate.
Execution riskMediumSuccessful margin expansion relies heavily on effective supply chain management and cost discipline.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 39.74B USD
Price to earnings Ratio 18.5
1Y Target Price 10.4
Price to earnings Ratio 18.5
1Y Target Price 10.4
Volume (30-day avg) 20.6M shares
Beta 0.29
52 Weeks Range 8.38 - 11.06
Updated Date 11/19/2026
52 Weeks Range 8.38 - 11.06
Updated Date 11/19/2026
Dividends yield (FY) 2.18%
Basic EPS (TTM) 0.49

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
61.0%
Active BUY / eligible
64 / 105
30-Day BUY Count Change
+16
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
91.7%
Active BUY / eligible
11 / 12
30-Day BUY Count Change
+5

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -23.83%
Avg. Invested days 34
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/19/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
HLN receives a 4-star rating, supported by solid unit economics, and solid quantitative characteristics. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
HLN has moderate overall fundamentals (3 stars), with solid financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, solid earnings growth (+15.6%) and strong cash generation (FCF margin 21.0%) are partially offset by slightly negative revenue growth (-1.8%), very low insider ownership of 0.03%.

Financial Health Rating

★★★★★
HLN's financial health is supported by strong cash strength, including free-cash-flow generation of $2.3B (21.0% of revenue). Liquidity is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is HLN's strongest growth driver at +15.6% FY2025 versus FY2024 (solid, 4 stars). By comparison, free-cash-flow growth (+12.7%, solid) is also solid, while revenue growth (-1.8%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 15.7% (soft) and 101.0% of outstanding shares are publicly tradable (strong). Insider ownership is only 0.03%, which materially reduces the ownership score.

Top 5 Institutional Investors

Dodge & Cox 3.37%
FMR Inc 2.72%
ClearBridge Advisors, LLC 0.73%
Morgan Stanley - Brokerage Accounts 0.44%
Harris Associates L.P. 0.38%

Unit Economics (Per $1K Revenue)

★★★★★
HLN generates approximately $642 of gross profit, $219 of operating income, and $210 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins and strong cash conversion support the rating, although capital efficiency remains soft.

Economic Dimensions

★★★★★
Effective Tax Rate: 21.93%

Quantitative Style Profile

★★★★★
HLN has a high-quality, large-cap, liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedQuality TiltLow VolatilityLarge / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Oral HealthGlobal sales of toothpaste, mouthwashes, and toothbrushes under brands like Sensodyne and Parodontax.This is a primary profit driver underpinned by daily consumer habit routines.
Pain ReliefOver-the-counter analgesic medications and topical gels such as Panadol and Voltaren.Provides high-margin, consistent cash flow across seasonal cold and flu periods.
Vitamins, Minerals and Supplements (VMS)Nutritional products marketed globally under names like Centrum and Caltrate.Captures secular wellness and preventative health spending trends.
Respiratory and Digestive HealthRemedies targeting cold, flu, and gastrointestinal ailments including Theraflu and ENO.Revenue fluctuates somewhat with seasonal illness outbreaks.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE 18.5
Forward PE 15.27
Enterprise Value 49.50B
Price to Sales(TTM) 3.56
Enterprise Value 49.50B
Price to Sales(TTM) 3.56
Enterprise Value to Revenue 3.39
Enterprise Value to EBITDA 13.46
Shares Outstanding 4.38B
Shares Floating 4.43B
Shares Outstanding 4.38B
Shares Floating 4.43B
Percent Insiders 0.03
Percent Institutions 15.71

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.